modelMegestrol
Extends from Pharmacolibrary.Drugs.ATC.G.G03AC05.
Information
| name: | Megestrol | |
| ATC code: | G03AC05 | route: | oral |
| compartments: | 1 | |
| dosage: | 160 | mg |
| volume of distribution: | 50 | L |
| clearance: | 1.5 | L/hr |
| other parameters in model implementation | ||
Megestrol is a synthetic progestin, primarily used as megestrol acetate to stimulate appetite and promote weight gain in patients with anorexia, cachexia, or significant weight loss due to cancer or AIDS. It has also been used in the palliative treatment of advanced breast and endometrial cancers. Megestrol acetate is approved and used in clinical practice today for these indications.
Pharmacokinetics
Pharmacokinetics parameters estimated for healthy adult subjects after oral administration, as published data are scarce. Estimates are derived from pharmacokinetic summaries and reviews where explicit PK parameters are not fully detailed.
References
Kim, YH, et al., & Bae, KS (2015). Tolerability and pharmacokinetics of two formulations of megestrol acetate under fed conditions in healthy volunteers. Clinical therapeutics 37(2) 439–447. DOI:10.1016/j.clinthera.2014.09.022 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25450470
Post, TM, et al., & de Greef, R (2016). Prediction of nomegestrol acetate pharmacokinetics in healthy female adolescents and adults by whole-body physiology-based pharmacokinetic modelling and clinical validation. Contraception 93(2) 133–138. DOI:10.1016/j.contraception.2015.08.017 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26365792
Markman, M, et al., & Belinson, J (2000). Phase I trial of paclitaxel plus megestrol acetate in patients with paclitaxel-refractory ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 6(11) 4201–4204. PUBMED:https://pubmed.ncbi.nlm.nih.gov/11106232
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)